CYTOKINETICS, INCORPORATED
CYTK US23282W6057
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 133% | -0% | 88% | -44% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Malik Fady Ibraham EX VP |
60.56 USD |
2,000 Sold |
121,120 USD |
07/10/2025 | 07/10/2025 |
| Malik Fady Ibraham EX VP |
60.56 USD |
2,000 Sold |
121,120 USD |
07/10/2025 | 07/10/2025 |
| Kaye Edward M. Md |
60.00 USD |
6,757 Sold |
405,420 USD |
06/10/2025 | 06/10/2025 |
| Blum Robert I CEO |
55.05 USD |
5,000 Sold |
275,250 USD |
01/10/2025 | 01/10/2025 |
| Kaye Edward M. Md |
55.08 USD |
6,695 Sold |
368,761 USD |
30/09/2025 | 30/09/2025 |
| Malik Fady Ibraham EX VP |
49.28 USD |
2,000 Sold |
98,560 USD |
23/09/2025 | 23/09/2025 |
| Blum Robert I CEO |
49.77 USD |
5,000 Sold |
248,850 USD |
15/09/2025 | 15/09/2025 |
| Malik Fady Ibraham EX VP |
51.29 USD |
2,000 Sold |
102,580 USD |
09/09/2025 | 09/09/2025 |
| Blum Robert I CEO |
48.76 USD |
5,000 Sold |
243,800 USD |
02/09/2025 | 02/09/2025 |
| Kaye Edward M. Md |
50.00 USD |
6,756 Sold |
337,800 USD |
02/09/2025 | 02/09/2025 |